SCHEMBL5772814

SCHEMBL5772814

COC(OC)c1ccn2ccnc2n1

nearest known ligand 0.35

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.35
RAB9A P51151 5/20 0.34
KDM4E B2RXH2 5/20 0.34
ALDH1A1 P00352 5/20 0.34
GAA P10253 4/20 0.34
NPC1 O15118 4/20 0.34
GLA P06280 3/20 0.34
POLB P06746 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
KMT2A Q03164 4/20 0.33
MAPT P10636 3/20 0.33
HPGD P15428 4/20 0.31
MEN1 O00255 1/20 0.30
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6218432 0.80 KDM5B (0.33) SMN1; SMN2RAB9AKDM4EALDH1A1GAA
SCHEMBL6220092 0.77 KDM4E (0.31) RAB9AKDM4EALDH1A1GAANPC1
SCHEMBL6218273 0.77 DYRK1A (0.33) KDM4EALDH1A1GLAHPGDDYRK1A
SCHEMBL7225919 0.73 KDM4E (0.40) SMN1; SMN2RAB9AKDM4EALDH1A1GAA
SCHEMBL6217345 0.71
SCHEMBL6222905 0.70 KDM4E (0.43) SMN1; SMN2RAB9AKDM4EALDH1A1GAA
SCHEMBL6102107 0.70 ALDH1A1 (0.39) SMN1; SMN2RAB9AKDM4EALDH1A1GAA
SCHEMBL5771081 0.69 KDM4E (0.34) SMN1; SMN2RAB9AKDM4EALDH1A1GAA
SCHEMBL6217690 0.69 HPGD (0.41) SMN1; SMN2RAB9AKDM4EALDH1A1GAA
SCHEMBL6217150 0.69 SMN1; SMN2 (0.33) SMN1; SMN2RAB9AKDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383768-B1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2006-09-06 EP disclosed
EP-1381606-B1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2005-07-20 EP disclosed
US-6642229-B2 Treatment of adverse neurological conditions MERCK SHARP & DOHME LTD. 2003-11-04 US disclosed